AI in Regulatory Affairs: Regulatory Intelligence, eCTD Writing, Labeling and Submission QC for Pharma and Medtech

What a regulatory affairs team hands to AI

A regulatory function writes few documents from nothing. It assembles, summarises and checks text that other functions produced: clinical study reports, nonclinical reports, batch analyses, stability data, validation reports, risk files and years of correspondence with health authorities. It then keeps that material consistent across regions, procedures and versions for the life of the product.

That makes the work a natural fit for language models, which read and compare large volumes of text well. It also makes the work sensitive. Almost every input is confidential to the company or to a licensing partner, and every output may end up in a legally binding submission. This guide covers the main tasks in the order a product moves through them, then turns to what EMA and FDA have said, data integrity, confidentiality and tool choice. Regulator sources were read on their own sites on 25 October 2026.

AI in regulatory intelligence: monitoring what changed

Regulatory intelligence means knowing, before a competitor or an inspector does, that a guideline, a procedure or an agency expectation has changed. The volume is the problem. FDA, EMA, the European Commission, ICH, national authorities and notified bodies publish guidance, Q&As, templates and technical specifications every week.

AI helps in three steps. A monitoring agent collects new and updated documents from a fixed list of sources. A model summarises each item, notes what changed from the previous version, and tags it to products, procedures or functions. A regulatory specialist reviews the shortlist and decides what needs action. The value is in the second step, because comparing a revised guideline with its predecessor is slow by hand.

Two recent examples show why a change log matters. EMA opened optional use of eCTD v4.0 for new centrally authorised marketing authorisation applications on 22 December 2025, and in July 2026 confirmed it will strongly recommend the format from the first quarter of 2027 and require it for those applications from the first quarter of 2028. In parallel, the European Commission’s new Variations Guidelines applied from 15 January 2026, on top of Regulation (EU) 2024/1701, which has applied since 1 January 2025. Both changed what a submission looks like, and both were announced through pages that many teams do not check every week. The compliance and regulation monitoring use case describes this pattern of source monitoring with reviewer triage.

AI for regulatory writing: Module 2 summaries and Module 3 quality

The Common Technical Document gives regulatory writing a fixed structure, which is the condition under which AI drafting works best.

Module 2 summaries. The quality overall summary, nonclinical and clinical overviews and summaries condense hundreds of pages of reports. A model can produce a first draft section by section if it works only from the cited source documents and links each statement to the report and page it came from. Medical writers then edit for emphasis and scientific judgement, which no model should own.

Module 3 quality. Sections on manufacture, specifications, batch analyses and stability are dense with numbers that must match the underlying reports. AI is useful here less as a writer and more as a checker: extracting values from certificates of analysis and stability reports, populating tables, and flagging any figure that differs between Module 3 and the summary in Module 2.

The structure itself is moving. ICH endorsed a draft revision of the quality CTD, M4Q(R2), in May 2025. ICH’s work plan of July 2026 says the public consultation closed with more than 2,500 comments and targets final adoption in June 2027. On the electronic side, FDA has accepted new applications in eCTD v4.0 since 16 September 2024, and the EU timeline above applies to centralised applications. Teams that keep content as structured, reusable sections rather than locked documents will find both transitions easier, and AI tools work better on that kind of content too. The regulatory submission assistant playbook shows specialist agents drafting and validating sections from a shared knowledge graph of CMC, clinical and regulatory documents.

Health authority query responses

A list of questions from an agency comes with a deadline, and the answers often already exist in pieces: a response to a similar question in another region, a stability update, a validation addendum, a statement in a prior meeting. Retrieval across past correspondence, commitments and source reports lets a model gather the relevant material for each question and draft a response with citations.

The risk is consistency rather than accuracy alone. An answer given to one agency becomes part of the product’s regulatory history and can later be set beside what the company told another authority. A good workflow shows the regulatory lead every prior answer on the same topic, flags conflicts with earlier commitments, and records which sources supported the draft. The decision on what to commit to stays with people.

Labeling: SmPC and USPI consistency checks

Product information is where small inconsistencies cause the most trouble: a dose in the SmPC that differs from the leaflet, a contraindication added in one region but not another, or a translation that drifted. Comparing the company core data sheet, the EU SmPC, the US prescribing information and national leaflets section by section is a task models do well, provided they flag differences rather than resolve them.

EMA’s reflection paper addresses this directly. It says AI used to draft, compile, edit, translate, tailor or review product information should be used under close human supervision, and that quality review must confirm that generated text is factually and syntactically correct before submission. That is a useful design brief for any labeling tool: every change it proposes should be visible, attributable and approved by a named person.

Variation and supplement impact assessment

When manufacturing, quality or a supplier proposes a change, regulatory affairs has to work out what it touches and how to file it. In the EU that means classifying the variation under the revised guidelines. In the US, it means deciding between a prior approval supplement, a changes-being-effected supplement or an annual report under 21 CFR 314.70 for drugs.

AI can speed up the first half of that work. Given the change description, a model can search the registered dossier in each market to find every section that mentions the affected material, process or specification, list the documents that would need updating, and suggest a likely category with the passage of the guideline that supports it. The classification itself, and any judgement that a change is moderate rather than major, belongs to the regulatory professional. Where the change comes out of an investigation, the same retrieval layer can sit across deviation and CAPA records as well.

Submission quality control

Before publishing, a submission goes through checks that are tedious and easy to get wrong: cross-references that point to the right section, consistent product names and strengths, the same numbers in summaries and source modules, current document versions, and correct use of terms across hundreds of files. Automated checks for hyperlinks and file formats already exist in publishing tools. Language models add checks for meaning, such as a dosing statement that differs between two modules, or a study described as ongoing in one place and complete in another. They should report findings with locations, not edit files.

AI in regulatory affairs for medical devices

For device companies the equivalent work centres on technical documentation: the design history file and US submissions, and the technical documentation required under Annexes II and III of the EU Medical Device Regulation. The same tasks apply, with traceability as the central theme. AI can trace requirements to risks, risk controls and verification tests, find gaps where a requirement has no test, and draft summaries for submissions and notified body reviews.

Where the device itself contains AI, regulatory affairs also has to assemble AI-specific evidence, and in the EU the AI Act brings its own technical documentation duties for high-risk AI systems on top of the MDR file. A technical documentation generator that interviews system owners shows how that kind of structured file can be drafted from a guided interview.

What EMA and FDA have said about AI in regulatory work

EMA reflection paper. The reflection paper on the use of AI in the medicinal product lifecycle was adopted by CHMP on 9 September 2024 and by CVMP on 11 September 2024, after consultation on a 2023 draft. It takes a risk-based view, distinguishing uses with high patient risk from those with high regulatory impact. It places responsibility on the sponsor, applicant, marketing authorisation holder or manufacturer to make sure every algorithm, model, dataset and data pipeline they use is fit for purpose, and it advises early contact with regulators where AI could affect the benefit-risk balance.

EMA and HMA guiding principles for large language models. Dated 29 August 2024 and published on 5 September 2024, these are written for staff across the European medicines regulatory network. They tell users to understand whether a model is deployed locally under the organisation’s control or is an open online service that may reuse prompts, and to keep personal data, trade secrets, intellectual property and contract-restricted data out of prompts. They also ask users to cross-check outputs, ask the model to quote the source text so it can be verified, and consider disclosing when a text is mostly model-generated. Written for regulators, they read equally well as a policy for an applicant’s regulatory team.

EMA AI workplan. The HMA and EMA multi-annual AI workplan runs from 2023 to 2028 and was first published in December 2023. The network’s data steering group workplan for 2025 to 2028 now carries the AI work forward across guidance, tools, collaboration and experimentation, and in March 2026 EMA extended its internal Scientific Explorer search tool to initial marketing authorisation applications.

FDA. FDA’s January 2025 draft guidance on using AI to support regulatory decision-making for drugs and biologics sets out a seven-step credibility framework for models that produce evidence on safety, effectiveness or quality. It explicitly excludes operational uses such as drafting a regulatory submission, as long as they do not affect patient safety, drug quality or study reliability. It was still a draft on 25 October 2026. On 14 January 2026 FDA and EMA published ten shared principles of good AI practice in drug development, including a clear context of use, data governance and documentation, and life cycle management.

Data integrity and ALCOA+ for AI-assisted records

Regulatory submissions rest on GxP records, so AI that touches them inherits data integrity expectations. FDA’s 2018 data integrity guidance for drug CGMP expects data to be attributable, legible, contemporaneously recorded, original or a true copy, and accurate. PIC/S guidance PI 041-1 of July 2021 adds complete, consistent, enduring and available, the set usually called ALCOA+.

For an AI-assisted draft, that translates into concrete requirements. The record should show who asked for the draft, which model and version produced it, which source documents it used, what the reviewer changed, and who approved the final text. If a model reads from a document repository, it should read controlled versions, and its outputs should not overwrite source records. Where the AI tool itself sits inside a GxP process, validation applies; our guide to validating AI and LLMs under GxP covers how far to take it.

Why regulatory teams want models they control

Unpublished dossiers are among the most confidential documents a life sciences company holds. In the US, FDA will not disclose the existence of a new drug application before approval unless it has already been made public, and the data in an application is not available for public disclosure before the approval letter, under 21 CFR 314.430. Sponsors protect the same material with equal care, and licensing and co-development agreements often restrict who may process a partner’s data.

That raises three questions for any AI tool: where prompts, documents and outputs are stored, who at the provider can access them, and whether the provider may retain them. EMA’s own LLM principles start from the same distinction between models an organisation controls and online services that may reuse inputs. For regulatory intelligence on public documents, an enterprise cloud assistant may be acceptable. For Module 3 data, query responses and partner documents, many teams keep processing on infrastructure they run. The questions to put to any vendor are collected in the enterprise AI procurement guide, and our overview of private AI for pharmaceutical and life sciences companies covers the wider deployment choices.

Human sign-off on every regulatory submission

The rule that matters most is simple. AI drafts, checks and retrieves; a qualified person decides and signs. In practice that means:

• every AI-produced statement carries a citation to a controlled source document;
• a named reviewer approves each section, and the approval is recorded;
• nothing reaches an agency gateway without the regulatory lead’s release;
• the AI tool cannot submit, publish or change controlled records on its own;
• prompts, sources, outputs and approvals are retained for as long as the submission records are.

How VDF AI fits a regulatory affairs team

VDF AI is software a company installs on its own servers, in a private cloud or in an air-gapped environment, and it can run local open-weight models only, so unpublished dossiers, CMC data and agency correspondence are not sent to an outside model provider. It is not a regulatory information management system or a publishing tool, and it holds no regulatory certification of its own; validation and compliance remain within the customer’s quality system.

For regulatory work, each product or procedure can have its own knowledge collection, and retrieval respects those permissions, so a team working on an unannounced filing sees only the documents it is entitled to see. A knowledge chat over compliance documents built without code is a common first step. Governed agents then take on repeatable tasks such as regulatory intelligence triage, labeling comparison, variation impact mapping and submission consistency checks, with tool permissions set per role and a human approval step before anything leaves the team. Each turn records who asked, which model answered and which passages it relied on, which supports the ALCOA+ record described above.

The VDF AI Router registers models served through Ollama, vLLM or other OpenAI-compatible endpoints and can admit approved cloud models for public-source tasks such as agency monitoring where policy allows. On-premises, Microsoft Entra ID single sign-on is native, and Okta, Keycloak and other SAML or OIDC providers connect through an SSO-aware reverse proxy; role-based access control is included in every plan. A three-month platform trial is available with each on-premises seat bundle, which gives a regulatory team time to test it against a real variation or query cycle.

The healthcare and life sciences solution page and the use case hub for healthcare AI describe the wider setup. Before a pilot, the free AI readiness assessment shows whether document access, validation or skills will hold up a first regulatory use case. This guide is general information, not regulatory advice for any specific product or procedure.